Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

Ionis Pharmaceuticals, Inc.

IONS

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of Ionis Pharmaceuticals, Inc.. A complete text table follows the diagram.

Ionis Converts Commercial and Research Collaborations Into Revenue

Commercial revenue and research-and-development revenue create two biotech monetization paths.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0000874015-26-000177
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

Labels and displayed flow values are reported filing values or exact disclosed subtotals.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

The filing discloses research-and-development revenue and total revenue; commercial revenue is the exact residual.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
Ionis Pharmaceuticals revenue	1	$246M	$246.1M reported quarterly revenue
Commercial revenue	2	$108M	Exact residual to total revenue
Research and development revenue	2	$138M	56% of total revenue

Financial flows · Millions of USD
From	To	Value
Ionis Pharmaceuticals revenue	Commercial revenue	$108M
Ionis Pharmaceuticals revenue	Research and development revenue	$138M